EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging

Huanhuan Liu, Xiaojun Zhang, Jingfeng Zhang, Yue Pan, Hui Wen, Xiaodan Xu, Shina Wu, Yuan Wang, Cong Zhang, Guangyu Ma, Yachao Liu, Ruimin Wang und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07131-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Huanhuan Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Copper Radioisotopes, Prostatic Neoplasms, Chelating Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aims to investigate the efficacy and safety of prostate-specific membrane antigen (PSMA) radiolabeled with copper-64 (64Cu) using the bifunctional chelating agents (BFCAs) NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). As widely utilized BFCAs in the development of radiopharmaceuticals, NOTA and DOTA play a critical role in ensuring stable chelation with 64Cu. This study evaluates the stability, bioavailability, and therapeutic potential of these radiolabeled compounds in preclinical models and initial clinical trials. METHODS: 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q were synthesized by manual labeling. The radiochemical purity, stability, specificity and biological distribution of the product were evaluated by preclinical studies. In 23 patients with suspected prostate cancer, PET/CT imaging was used to evaluate the potential and differences in biological distribution of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q in clinical diagnosis. RESULTS: The radiochemical purities of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q are more than 98% and have good stability in vitro. Biodistribution studies in healthy mice revealed that both tracers primarily underwent renal excretion post-injection. Liver uptake of 64Cu-DOTA-PSMA-3Q was significantly higher than that of 64Cu-NOTA-PSMA-3Q at 1 h after injection (P 0.05). However, after 24 h, 64Cu-DOTA-PSMA-3Q exhibited significantly better tumor retention compared to 64Cu-NOTA-PSMA-3Q (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyCopper RadioisotopesProstatic NeoplasmsChelating AgentsHeterocyclic CompoundsHeterocyclic Compounds, 1-RingGlutamate Carboxypeptidase IIMaleAnimalsHumansMiceCell Line, TumorTissue DistributionRadiopharmaceuticals

Stichwörter der Autor:innen

64Cu-DOTA-PSMA-364Cu-NOTA-PSMA-3QBifunctional chelating agentProstate cancerQPSMA-PET/CT

Substanzen

Copper RadioisotopesChelating AgentsHeterocyclic CompoundsHeterocyclic Compounds, 1-RingCopper-641,4,7-triazacyclononane-N,N',N''-triacetic acidRadiopharmaceuticalsGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
  • Medical School of Chinese PLA, Beijing, 100853, China.
  • Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. yachao301@163.com.
  • Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. wrm@yeah.com.
  • Department of Nuclear Medicine, The First Medical Centre, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. zhangjm301@163.com.

ORCID-Profile: Jinming Zhang

Zitieren

APA

Liu, H., Zhang, X., Zhang, J., Pan, Y., Wen, H., Xu, X., Wu, S., Wang, Y., Zhang, C., Ma, G., Liu, Y., Wang, R., & Zhang, J. (2025). Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07131-3

Vancouver

Liu H, Zhang X, Zhang J, Pan Y, Wen H, Xu X, et al. Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07131-3

BibTeX
@article{Liu2025,
  author = {Liu, Huanhuan and Zhang, Xiaojun and Zhang, Jingfeng and Pan, Yue and Wen, Hui and Xu, Xiaodan and Wu, Shina and Wang, Yuan and Zhang, Cong and Ma, Guangyu and Liu, Yachao and Wang, Ruimin and Zhang, Jinming},
  title = {Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07131-3}
}
Kostenlos starten →